Table 2.

Diabetes treatment regimens administered to older Veterans with potentially overtreated diabetes living in Community Living Centers with limited life expectancy or advanced dementia, overall and stratified by baseline HbA1c (N=3,056).¹

		Stratified by baseline HbA1c, %
Treatment Administered, %	Overall (N=3,056)	<6.0 (n=811)	6.0-<6.5 (n=769)	6.5-<7.0 (n=816)	7.0–7.5 (n=660)
Number of diabetes medications used
1	53.1	61.5	59.0	50.2	39.4
2	41.9	35.6	37.8	43.6	52.1
≥3	5.0	2.8	3.1	6.1	8.5
Most common treatment regimens2
Short-acting insulin and basal insulin	28.6	23.4	24.6	31.5	35.9
Short-acting insulin only	16.0	19.7	15.5	15.4	12.7
Basal insulin only	13.7	15.4	13.4	13.8	11.8
Sulfonylureas only	13.8	14.9	18.3	13.0	8.0
Non-insulin / non-sulfonylurea agent only	9.8	11.6	12.1	8.0	7.0
Short-acting insulin and sulfonylureas	5.0	4.3	5.5	3.8	6.8
Sulfonylureas and non-insulin / non-sulfonylurea agent	3.5	3.2	2.6	4.7	3.6
Short-acting insulin and non-insulin / non-sulfonylurea agent	2.6	2.8	2.5	2.0	3.2
Other regimens3	7.1	4.6	5.6	7.8	10.9
High-risk hypoglycemic agents	75.3	71.9	73.2	77.3	79.4
Short-acting insulin	56.7	52.9	50.7	58.2	66.7
Sulfonylurea	26.4	25.0	29.8	27.1	23.3

¹Diabetes medications and treatment regimens were classified based on medications administered on the day of and day following the first HbA1C measurement following admission to the Community Living Center

²Treatment regimens were classified after grouping medications into basal insulin, short-acting insulin, sulfonylureas, and non-insulin / non-sulfonylurea hypoglycemic agents. Most common treatment regimens are mutually exclusive and add to 100%.

³3Includes all other regimens with a prevalence <2.0%. Note: all other regimens contained ≥3 of basal insulin, short-acting insulin, sulfonylureas, and non-insulin / non-sulfonylurea agents except for 1) basal insulin and other non-insulin / non-sulfonylurea use (1.2%) and 2) basal insulin and sulfonylurea use (1.1%).